Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Aggarwal and Gandara on Incorporating Liquid Biopsies Into the Lung Cancer Armamentarium

November 9th 2020

In our exclusive interview, Dr. Aggarwal and Dr. Gandara discuss the evolution of liquid biopsy in lung cancer, explain the clinical implications of recent liquid biopsy approvals, and forecast the future of liquid biopsy in the field.

FDA Approves FoundationOne Liquid CDx as Companion Diagnostic for Olaparib in Prostate Cancer

November 9th 2020

The FDA has approved the FoundationOne Liquid CDx for use as a companion diagnostic with olaparib, which is indicated for select patients with deleterious or suspected deleterious germline or somatic homologous recombination repair gene–mutated metastatic castration-resistant prostate cancer.

Need for Germline Testing Becomes Increasingly Pronounced in Oncology

November 6th 2020

Mark E. Robson, MD, discusses how a strong cognizance of germline testing is becoming increasingly important in the field of oncology, across an array of tumor types.

Dr. Luke on the Role of Targeted Therapy in Melanoma

November 4th 2020

Jason J. Luke, MD, FACP, discusses the role of targeted therapy in melanoma.

FDA Approves First Companion Diagnostic for Expanded EGFR TKIs in NSCLC

October 30th 2020

The FDA has approved the cobas EGFR Mutation Test v2 as a companion diagnostic for EGFR TKIs in the treatment of patients with EGFR-mutated non–small cell lung cancer.

ESMO 2020 Highlights With Cora Sternberg, MD, FACP

October 30th 2020

TROPHY U-01 cohort 1 is a phase 2 open-label study of sacituzumab govitecan in patients with metastatic urothelial cancer and disease progression after both platinum-based regimens and checkpoint inhibitors.

Dr. Shore on the Need for Further Education on Molecular Testing in mCRPC

October 29th 2020

Neal D. Shore, MD, FACS, discusses the need for further education on molecular testing for metastatic castration-resistant prostate cancer.

Raez on the Rise of Liquid Biopsy in Lung Cancer

October 29th 2020

In our exclusive interview, Dr. Raez provides insight into the advantages and disadvantages of liquid biopsy relative to tissue biopsy and forecasts the utility of liquid biopsy within the field of lung cancer as more of these assays become available.

ESMO 2020 Highlights With Aditya Bardia, MD, MPH

October 29th 2020

Aditya Bardia, MD, MPH, discusses the results of the ASCENT trial in triple-negative breast cancer.

Beat AML Master Clinical Trial Showcases Paradigm Shift With Precision Medicine

October 28th 2020

Delaying treatment for up to 7 days so that genomic data can be utilized to inform a personalized treatment approach is safe, feasible, and can improve overall survival in patients with acute myeloid leukemia.

Role of Trop-2 as an Actionable Biomarker in Solid Tumors

October 28th 2020

Trophoblast cell surface antigen 2 is a glycoprotein that spans the epithelial membrane surface and plays a role in cell self-renewal, proliferation, and transformation.

FDA Approves FoundationOne Liquid CDx For New Indications in Advanced Ovarian, Breast, and NSCLC

October 27th 2020

The FDA has approved the FoundationOne Liquid CDx for use as a companion diagnostic for 3 targeted therapies: alpelisib in advanced or metastatic breast cancer, rucaparib in advanced ovarian cancer, and alectinib in a specific type of metastatic non–small cell lung cancer.

Next-Generation BRAF Inhibitor Plus Cobicistat Elicits Encouraging Activity in BRAF+ Refractory Solid Tumors

October 26th 2020

PLX8394, a next-generation BRAF inhibitor, in combination with cobicistat was found to demonstrate encouraging clinical activity with an acceptable safety profile in patients with BRAF-mutated, refractory solid tumors.

FDA Approves FoundationOne CDx for Larotrectinib in NTRK+ Tumors

October 23rd 2020

The FDA has approved the FoundationOne CDx comprehensive genomic test as a companion diagnostic for larotrectinib (Vitrakvi) to identify patients with NTRK1/2/3 gene fusions across all solid tumors.

MD Anderson and Taiho Pharmaceutical Collaborate to Develop Therapies for Brain Metastases

October 23rd 2020

The University of Texas MD Anderson Cancer Center and Taiho Pharmaceutical have formed a collaboration to do preclinical and early clinical research on potential therapies to treat brain metastases and those with cancers refractory to available therapies.

Subbiah Addresses Controversy Surrounding Pembrolizumab Approval for TMB-High Tumors

October 22nd 2020

In a special episode of OncLive On AirTM Vivek Subbiah, MD, discusses the FDA approval of pembrolizumab in TMB-high solid tumors and addressed the controversy surrounding the approval.

Novel Strategies for Targeting the “Guardian of the Genome” Emerge

October 22nd 2020

p53 presents a significant challenge for investigators, and the field is littered with clinical trial failures and abandoned drug development programs.

IDE196/Crizotinib Combo Under Exploration in GNAQ/11+ Solid Tumors

October 18th 2020

An ongoing, collaborative clinical trial has been expanded to evaluate the investigational protein kinase C inhibitor IDE196 in combination with the multikinase inhibitor crizotinib (Xalkori) for patients with GNAQ- or GNA11-mutated solid tumors, including metastatic uveal melanoma , skin melanoma, lung cancer, and colorectal cancer.

Garcia-Manero Previews Potential Therapeutic Standards in TP53-Mutated MDS/AML

October 15th 2020

In our exclusive interview, Guillermo Garcia-Manero, MD, discusses the prevalence of TP53 mutations in myelodysplastic syndromes and acute myeloid leukemia, the prognosis these mutations confer, and the development of eprenetapopt and magrolimab in this patient population.

COVID-19 Raises the Stakes of Preventive Medicine in Oncology

October 13th 2020

Anna Giuliano, PhD, discusses the work efforts to advance the reach of preventive vaccines and cancers, and the challenges researchers are facing in the process.